Myasthenia gravis requiring pyridostigmine treatment in a national population cohort

Abstract

Reported prevalence and incidence are amongst the highest found in similar studies. This may be explained by optimal case identification, higher incidence of drug requiring MG amongst the elderly, and recurrences of previous MG.

Cholinesterases, a Target of Pharmacology and Toxicology

“…Physostigmine is a strong reversible inhibitor of AChE. It has broad use in Myasthenia gravis treatment as it increases acetylcholine levels in the damaged neurosynaptic clefts and also as a prophylactic to nerve agent exposure as it blocks the irreversible binding of nerve agents 92,93 . Carbamates are pseudoirreversible inhibitors of cholinesterases; the carbamoyl moiety can be split from cholinesterase by spontaneous hydrolysis 94 .…”

Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries

“…Nationwide registries covering whole populations are emerging, providing a sound basis for epidemiological studies (11)(12)(13). The AChR antibody database (AAD) and the Norwegian Prescription Database (NorPD) have been utilized by our research group to elucidate the epidemiology of MG in a complete national cohort (14)(15)(16) (17)(18)(19). Use of pyridostigmine is therefore considered a reliable indicator of MG requiring symptomatic treatment (16,20,21).…”

“…The AChR antibody database (AAD) and the Norwegian Prescription Database (NorPD) have been utilized by our research group to elucidate the epidemiology of MG in a complete national cohort (14)(15)(16) (17)(18)(19). Use of pyridostigmine is therefore considered a reliable indicator of MG requiring symptomatic treatment (16,20,21). Three studies with reports on MG prevalence and incidence have until now been published based on these two databases (14)(15)(16).…”

“…Use of pyridostigmine is therefore considered a reliable indicator of MG requiring symptomatic treatment (16,20,21). Three studies with reports on MG prevalence and incidence have until now been published based on these two databases (14)(15)(16).…”

Análise do jitter com agulha concêntrica em pacientes com miastenia gravis autoimune adquirida

“…A MG tem prevalência de 40 a 180 por milhão de pessoas e incidência anual de 4 a 12 por milhão de pessoas, com distribuição bimodal relacionada com a idade (Heldal et al, 2009;Andersen et al, 2010;Carr et al, 2010 (Oosterhuis, 1989;Drachman, 1994;Vincent et al, 2001;Keesey 2004). Aproximadamente 10% a 20% dos pacientes com MG apresentam timoma, e tipicamente esses pacientes apresentam fraqueza generalizada e ac-AChR positivo (Keesey, 2004;Marx et al, 2013).…”